Oncology | New Developments | UNITED STATES

Pfizer Inc

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Contact Supplier

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

IDEAYA and Pfizer Enter Clinical Trial Collaboration and Supply Agreement

Lead Product(s): IDE196,Binimetinib

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: Ideaya Biosciences

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration March 18, 2020

Details:

IDEAYA and Pfizer will form a Joint Development Committee (JDC), and there will be joint decision making and data sharing of the clinical trial results between the parties.

Aldevron

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Aldevron Announces Agreement with Ziopharm Oncology for neoGMP® Production of Sleeping Beauty Plasmid DNA

Lead Product(s): DNA plasmids

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Ziopharm Oncology

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement June 26, 2020

Details:

Ziopharm, based on their analyses of patient tumors, will identify TCRs on a patient-by-patient basis as well as assemble TCRs in a library for use in clinical trials. The company will use Aldevron’s neoGMP service to manufacture multiple DNA plasmids in an expedient.

Merck & Co. Inc.

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Linnaeus Therapeutics Announces Clinical Trial Collaboration Agreement with Merck to Evaluate LNS8801 in Combination with KEYTRUDA

Lead Product(s): LNS8801,Pembrolizumab

Therapeutic Area: Oncology Product Name: LNS8801

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: Linnaeus Therapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration June 23, 2020

Details:

Collaboration agreement aims to study the combination of Linnaeus's lead investigational drug candidate LNS8801, and Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in patients with selected advanced solid tumors.

Tanabe Research Laboratories

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Adagene Announces Strategic Collaboration Agreement with Tanabe Research Laboratories

Lead Product(s): Masked antibody drug conjugate

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Adagene (Suzhou) Limited

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration June 10, 2020

Details:

Under the terms of this collaboration, TRL will use Adagene’s SAFEbody™ technology platform to generate a masked antibody in combination with the cytotoxic payload technologies used at TRL, for the development of an ADC against a solid tumor target.

Everest Medicines

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Everest Medicines Completes US$310 Million Series C Financing

Lead Product(s): Sacituzumab Govitecan

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Janchor Partners

Deal Size: $310.0 million Upfront Cash: Undisclosed

Deal Type: Series C Financing June 05, 2020

Details:

Proceeds from the financing will be used to advance clinical development of Everest Medicines’ robust pipeline of novel therapeutic candidates and build out a strong commercial infrastructure to support the next phase of growth.

Leidos

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Targovax Enters Collaboration With Leidos to add Checkpoint Inhibitor Functionality to ONCOS Viruses

Lead Product(s): ONCOS viruses,Microbially derived peptides

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Targovax

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration June 04, 2020

Details:

Leidos and Targovax will investigate the technical feasibility, in vitro and in vivo immune modulatory, and anti-cancer properties of encoding Microtide™ checkpoint peptides in the ONCOS adenovirus backbone.

Processa Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Processa Pharmaceuticals Has Entered into an Agreement with Aposense, to License in the Next Generation Irinotecan Drug

Lead Product(s): Irinotecan

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: Aposense

Deal Size: $127.5 million Upfront Cash: Undisclosed

Deal Type: Licensing Agreement June 01, 2020

Details:

Under this Condition Precedent License Agreement, Aposense will grant Processa a worldwide, royalty-bearing right and license, including the right to sublicense, their next generation irinotecan cancer drug, ATT-11T, upon satisfaction of the set conditions.

Foundation Medicine

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Foundation Medicine and Dana-Farber Present Data at ASCO20 Showing that Comprehensive Genomic Profiling Identified Co-Occurring Alterations ...

Lead Product(s): Undisclosed

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 29, 2020

Details:

The study emphasizes the importance of comprehensive genomic profiling in patients with METex14-altered NSCLC to facilitate precision medicine both earlier and throughout a patient’s treatment.

Merck & Co. Inc.

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

RefleXion Announces Clinical Collaboration to Evaluate Biology-guided Radiotherapy With Merck’s KEYTRUDA® for Certain Late-Stage Cancers

Lead Product(s): Pembrolizumab,BgRT

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: RefleXion Medical

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration May 28, 2020

Details:

The aim of the clinical collaboration between RefleXion and Merck is to establish whether treating multiple tumors with BgRT, a novel external beam radiotherapy treatment modality in development, is safe and amplifies KEYTRUDA’s therapeutic effect.

Immunai

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Immunai Raises $20M with an Immunology Focus

Lead Product(s): CAR-T cell therapies

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Viola Group

Deal Size: $20.0 million Upfront Cash: Undisclosed

Deal Type: Financing May 15, 2020

Details:

Immunai aims to map out the whole immune system. The funds will make a hiring push and will expand its already robust research and development activities.

Find

Find Novel Oncology Drugs in Clinical Development in UNITED STATES

United States

Product Type

Companies

Pfizer Inc

IDEAYA and Pfizer Enter Clinical Trial Collaboration and Supply Agreement

Aldevron

Aldevron Announces Agreement with Ziopharm Oncology for neoGMP® Production of Sleeping Beauty Plasmid DNA

Merck & Co. Inc.

Linnaeus Therapeutics Announces Clinical Trial Collaboration Agreement with Merck to Evaluate LNS8801 in Combination with KEYTRUDA

Tanabe Research Laboratories

Adagene Announces Strategic Collaboration Agreement with Tanabe Research Laboratories

Everest Medicines

Everest Medicines Completes US$310 Million Series C Financing

Leidos

Targovax Enters Collaboration With Leidos to add Checkpoint Inhibitor Functionality to ONCOS Viruses

Processa Pharmaceuticals

Processa Pharmaceuticals Has Entered into an Agreement with Aposense, to License in the Next Generation Irinotecan Drug

Foundation Medicine

Foundation Medicine and Dana-Farber Present Data at ASCO20 Showing that Comprehensive Genomic Profiling Identified Co-Occurring Alterations ...

Merck & Co. Inc.

RefleXion Announces Clinical Collaboration to Evaluate Biology-guided Radiotherapy With Merck’s KEYTRUDA® for Certain Late-Stage Cancers

Immunai

Immunai Raises $20M with an Immunology Focus